LATEST GI CANCERS CONTENT

Improved Survival Observed in CABINET Trial of Pancreatic NETs

NALIRIFOX Dose Reductions Maintain Efficacy in Pancreatic Cancer

Liposomal Irinotecan Is Active After Prior Treatment in Pancreatic Cancer

Key Takeaways of Trials in Metastatic CRC Explored

Physicians Consider Possible Outcomes of Treatment in Third-Line CRC

Understanding the Use of Nivolumab in the Current Upper GI Landscape

Five-Year Data Confirm Benefit of Nivolumab in Upper GI Cancer

KEYNOTE-859 Outcomes Influence NCCN Guidelines on Pembrolizumab in Upper GI Cancer
CASE-BASED ROUNDTABLES
Advertisement
Advertisement









